Skip to main content
SpringerLink
Log in

Antidiabetic Drugs in COVID-19

  • Chapter
  • First Online:
Cardiovascular Complications of COVID-19

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 271 Accesses

Abstract

Diabetes mellitus (DM) has been linked to COVID-19 incidence, severity, and worse outcomes. Antidiabetic drugs have been suggested to affect COVID-19 outcomes via several mechanisms, including their glucose-lowering, insulin sensitizing, immuno-modulatory, anti-inflammatory, and anti-oxidant effects. This chapter focuses on the impact of different antidiabetic agents (i.e., metformin, sulfonylureas, pioglitazone, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter 2 inhibitors, and insulin) on COVID-19 prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Katsiki N, Gómez-Huelgas R, Mikhailidis DP, Pérez-Martínez P. Narrative review on clinical considerations for patients with diabetes and COVID-19: more questions than answers. Int J Clin Pract. 2021;75(11):e14833.

    Article  CAS  Google Scholar 

  2. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30.

    Article  CAS  Google Scholar 

  3. Pettus J, Skolnik N. Importance of diabetes management during the COVID-19 pandemic. Postgrad Med. 2021;133(8):912–9.

    Article  CAS  Google Scholar 

  4. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, Klonoff DC. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–21.

    Article  CAS  Google Scholar 

  5. George TP, Joy SS, Rafiullah M, Siddiqui K. Cytokines in COVID-19 patients with diabetes: systematic review. Curr Diabetes Rev. 2022;18 https://doi.org/10.2174/1573399818666220118100743. Epub ahead of print.

  6. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era? J Diabetes Complicat. 2020;34(12):107723.

    Article  Google Scholar 

  7. Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, McNeil C, Feng R, Guzman G, Abdelwahab N, King S, Tamariz L, Meehan T, Pendleton KM, Benson B, Vojta D, Tignanelli CJ. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2(1):e34–41.

    Article  Google Scholar 

  8. Luo P, Qiu L, Liu Y, Liu XL, Zheng JL, Xue HY, Liu WH, Liu D, Li J. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg. 2020;103(1):69–72.

    Article  CAS  Google Scholar 

  9. Ojeda-Fernández L, Foresta A, Macaluso G, Colacioppo P, Tettamanti M, Zambon A, Genovese S, Fortino I, Leoni O, Roncaglioni MC, Baviera M. Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: a population-based study in Lombardy. Diabetes Obes Metab. 2022;24:891. https://doi.org/10.1111/dom.14648.

    Article  CAS  Google Scholar 

  10. Lalau JD, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M, Allix I, Amadou C, Bourron O, Duriez T, Gautier JF, Dutour A, Gonfroy C, Gouet D, Joubert M, Julier I, Larger E, Marchand L, Marre M, Meyer L, Olivier F, Prevost G, Quiniou P, Raffaitin-Cardin C, Roussel R, Saulnier PJ, Seret-Begue D, Thivolet C, Vatier C, Desailloud R, Wargny M, Gourdy P, Cariou B, CORONADO investigators. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 2021;47(5):101216.

    Article  CAS  Google Scholar 

  11. Lally MA, Tsoukas P, Halladay CW, O'Neill E, Gravenstein S, Rudolph JL. Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2. J Am Med Dir Assoc. 2021;22(1):193–8.

    Article  Google Scholar 

  12. Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne). 2021;11:600439.

    Article  Google Scholar 

  13. Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, Kar P, Meace C, Sattar N, Sharp S, Wareham NJ, Weaver A, Woch E, Young B, Valabhji J. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9(5):293–303.

    Article  CAS  Google Scholar 

  14. Ong AN, Tan CC, Cañete MT, Lim BA, Robles J. Association between metformin use and mortality among patients with type 2 diabetes mellitus hospitalized for COVID-19 infection. J ASEAN Fed Endocr Soc. 2021;36(2):133–41.

    Article  Google Scholar 

  15. Ganesh A, Randall MD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:2642. https://doi.org/10.1111/bcp.15258.

    Article  CAS  Google Scholar 

  16. Dehkordi AH, Abbaszadeh A, Mir S, Hasanvand A. Metformin and its anti-inflammatory and anti-oxidative effects; new concepts. J Renal Inj Prev. 2019;8(1):54–61.

    Article  CAS  Google Scholar 

  17. Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW, Ma RCW, Wong GL. Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. BMJ Open. 2021;11(10):e052310.

    Article  Google Scholar 

  18. Pazoki M, Chichagi F, Hadadi A, Kafan S, Montazeri M, Kazemian S, Aminorroaya A, Ebrahimi M, Ashraf H, Hazaveh MM, Khajavi MR, Moharari RS, Sharifnia SH, Saleh SK, Rahimzadeh H, Goodarzi N, Heydarian P. Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study. J Diabetes Metab Disord. 2021;20(2):1545–55.

    Article  CAS  Google Scholar 

  19. Boye KS, Tokar Erdemir E, Zimmerman N, Reddy A, Benneyworth BD, Dabora MC, Hankosky ER, Bethel MA, Clark C, Lensing CJ, Sailer S, San Juan R, Heine RJ, Etemad L. Risk factors associated with COVID-19 hospitalization and mortality: a large claims-based analysis among people with type 2 diabetes mellitus in the United States. Diabetes Ther. 2021;12(8):2223–39.

    Article  CAS  Google Scholar 

  20. Kan C, Zhang Y, Han F, Xu Q, Ye T, Hou N, Sun X. Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:708494.

    Article  Google Scholar 

  21. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43:1399–407.

    Article  CAS  Google Scholar 

  22. Kim MK, Jeon JH, Kim SW, Moon JS, Cho NH, Han E, et al. The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea. Diabetes Metab J. 2020;44:602–13.

    Article  Google Scholar 

  23. Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi E, Mazziotti G, Lania AG. Impact of comorbidities and Glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an Academic Hospital in Lombardy, Italy. Diabetes Care. 2020;43(12):3042–9.

    Article  CAS  Google Scholar 

  24. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500–15.

    Article  CAS  Google Scholar 

  25. Wargny M, Potier L, Gourdy P, Pichelin M, Amadou C, Benhamou PY, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the Nationwide CORONADO study. Diabetologia. 2021;64:778–94.

    Article  CAS  Google Scholar 

  26. Yanai H. The optimal medical therapy for glycemic control in COVID-19. J Endocrinol Metab. 2021;11(1):1–7.

    Article  CAS  Google Scholar 

  27. Ferraz WR, Gomes RA, Novaes ALS, Goulart Trossini GH. Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study. Future Med Chem. 2020;12(20):1815–28.

    Article  CAS  Google Scholar 

  28. Singh Tomar PP, Arkin IT. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine. Biochem Biophys Res Commun. 2020;530(1):10–4.

    Article  CAS  Google Scholar 

  29. Ciavarella C, Motta I, Valente S, Pasquinelli G. Pharmacological (or synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease. Molecules. 2020;25(9):2076.

    Article  CAS  Google Scholar 

  30. Carboni E, Carta AR, Carboni E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses. 2020;140:109776.

    Article  CAS  Google Scholar 

  31. Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, Nakagawa J, Sando Y, Shimizu Y, Suga T, Arai M, Kurabayashi M. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration. 2009;77(3):311–9.

    Article  CAS  Google Scholar 

  32. Barbarin V, Nihoul A, Misson P, Arras M, Delos M, Leclercq I, Lison D, Huaux F. The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis. Respir Res. 2005;6(1):112.

    Article  Google Scholar 

  33. Jagat JM, Kalyan KG, Subir R. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): boon or bane? Diabetes Metab Syndr. 2020;14(5):829–31.

    Article  Google Scholar 

  34. Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Leslie DL, Kraschnewski JL, Parent LJ, Grigson PS. Diabetes, drug treatment, and mortality in COVID-19: a multinational retrospective cohort study. Diabetes. 2021;70(12):2903–16.

    Article  CAS  Google Scholar 

  35. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–88.

    Article  CAS  Google Scholar 

  36. Singh AK, Singh R, Saboo B, Misra A. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: a critical appraisal of literature. Diabetes Metab Syndr. 2021;15(1):159–67.

    Article  Google Scholar 

  37. Sun B, Huang S, Zhou J. Perspectives of antidiabetic drugs in diabetes with coronavirus infections. Front Pharmacol. 2021;11:592439.

    Article  Google Scholar 

  38. Sibiya NH, Mkhize BC, Khathi A. DPP4 inhibitors: could they be one of the solutions for COVID-19 patients with prediabetes? Curr Rev Clin Exp Pharmacol. 2022; Epub ahead of print.

    Google Scholar 

  39. Yazbeck R, Jaenisch SE, Abbott CA. Dipeptidyl peptidase 4 inhibitors: applications in innate immunity? Biochem Pharmacol. 2021;188:114517.

    Article  CAS  Google Scholar 

  40. Zhao LM, Chen XH, Qiu M. Commentary: mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;12:825100.

    Article  Google Scholar 

  41. Rakhmat II, Kusmala YY, Handayani DR, Juliastuti H, Nawangsih EN, Wibowo A, Lim MA, Pranata R. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021;15(3):777–82.

    Article  Google Scholar 

  42. Yang Y, Cai Z, Zhang J. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: a meta-analysis. PLoS One. 2021;16(5):e0251916.

    Article  CAS  Google Scholar 

  43. Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021;20(1):543–50.

    Article  CAS  Google Scholar 

  44. Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: a bridge between diabetes and COVID-19, and possible management with sitagliptin. Med Hypotheses. 2020;143:110111.

    Article  CAS  Google Scholar 

  45. Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Alexiou A, Batiha GE. Impact of Sitagliptin in non-diabetic Covid-19 patients. Curr Mol Pharmacol. 2022;15:683–92.

    Article  CAS  Google Scholar 

  46. Solerte SB, D'Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, Dell'Acqua M, Ippolito E, Scaranna C, Bellante R, Galliani S, Dodesini AR, Lepore G, Geni F, Fiorina RM, Catena E, Corsico A, Colombo R, Mirani M, De Riva C, Oleandri SE, Abdi R, Bonventre JV, Rusconi S, Folli F, Di Sabatino A, Zuccotti G, Galli M, Fiorina P. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 2020;43(12):2999–3006.

    Article  CAS  Google Scholar 

  47. Al-Rabia MW, Alhakamy NA, Ahmed OAA, Eljaaly K, Alaofi AL, Mostafa A, Asfour HZ, Aldarmahi AA, Darwish KM, Ibrahim TS, Fahmy UA. Repurposing of Sitagliptin- Melittin optimized Nanoformula against SARS-CoV-2: antiviral screening and molecular docking studies. Pharmaceutics. 2021;13(3):307.

    Article  CAS  Google Scholar 

  48. Bardaweel SK, Hajjo R, Sabbah DA. Sitagliptin: a potential drug for the treatment of COVID-19? Acta Pharma. 2021;71(2):175–84.

    Article  CAS  Google Scholar 

  49. Guardado-Mendoza R, Garcia-Magaña MA, Martínez-Navarro LJ, Macías-Cervantes HE, Aguilar-Guerrero R, Suárez-Pérez EL, Aguilar-García A. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. Sci Rep. 2022;12(1):536.

    Article  CAS  Google Scholar 

  50. Abuhasira R, Ayalon-Dangur I, Zaslavsky N, Koren R, Keller M, Dicker D, Grossman A. A randomized clinical trial of Linagliptin vs. standard of care in patients hospitalized with diabetes and COVID-19. Front Endocrinol (Lausanne). 2021;12:794382.

    Article  Google Scholar 

  51. Rao PPN, Pham AT, Shakeri A, El Shatshat A, Zhao Y, Karuturi RC, Hefny AA. Drug repurposing: dipeptidyl peptidase IV (DPP4) inhibitors as potential agents to treat SARS-CoV-2 (2019-nCoV) infection. Pharmaceuticals (Basel). 2021;14(1):44.

    Article  CAS  Google Scholar 

  52. Lee JH. Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension. Med Hypotheses. 2022;158:110739.

    Article  CAS  Google Scholar 

  53. Sazgarnejad S, Yazdanpanah N, Rezaei N. Anti-inflammatory effects of GLP-1 in patients with COVID-19. Expert Rev Anti-Infect Ther. 2022;20(3):373–81.

    Article  CAS  Google Scholar 

  54. Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC, Kahn SE, Boyko EJ. Prior glucose-lowering medication use and 30-day outcomes among 64,892 veterans with diabetes and COVID-19. Diabetes Care. 2021;44(12):2708–13.

    Article  Google Scholar 

  55. Nguyen NN, Ho DS, Nguyen HS, Ho DKN, Li HY, Lin CY, Chiu HY, Chen YC. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis. Metabolism. 2022;131:155196.

    Article  CAS  Google Scholar 

  56. Kahkoska AR, Abrahamsen TJ, Alexander GC, Bennett TD, Chute CG, Haendel MA, Klein KR, Mehta H, Miller JD, Moffitt RA, Stürmer T, Kvist K, Buse JB, N3C Consortium. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care. 2021;44(7):1564–72.

    Article  CAS  Google Scholar 

  57. Banerjee Y, Pantea Stoian A, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, Rizzo M. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021;20(11):1309–15.

    Article  CAS  Google Scholar 

  58. Nevola R, Alfano M, Pafundi PC, Brin C, Gragnano F, Calabrò P, Adinolfi LE, Rinaldi L, Sasso FC, Caturano A. Cardiorenal impact of SGLT-2 inhibitors: a conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. Rev Cardiovasc Med. 2022;23(3):106.

    Article  Google Scholar 

  59. Katsiki N, Mikhailidis DP, Theodorakis MJ. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management. Curr Pharm Des. 2017;23(10):1522–32.

    Article  CAS  Google Scholar 

  60. Alshnbari A, Idris I. Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - targeting hyperinflammation. Curr Med Res Opin. 2022;38(3):357–64.

    Article  CAS  Google Scholar 

  61. Yaribeygi H, Katsiki N, Butler AE, Sahebkar A. Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discov Today. 2019;24(1):256–62.

    Article  Google Scholar 

  62. Fernandez-Fernandez B, D'Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, Porrini E, Sarafidis P, Soler MJ, Ortiz A. Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19. J Clin Med. 2020;9(7):2030.

    Article  CAS  Google Scholar 

  63. Cure E, Cumhur CM. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr. 2020;14(4):405–6.

    Article  Google Scholar 

  64. Qu H, Zheng Y, Wang Y, Li H, Liu X, Xiong X, Zhang L, Gu J, Yang G, Zhu Z, Zheng H, Ouyang Q. The potential effects of clinical antidiabetic agents on SARS-CoV-2. J Diabetes. 2021;13(3):243–52.

    Article  CAS  Google Scholar 

  65. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF, Aboudara M, Hoffmann Filho CR, Feitosa ADM, Fonseca A, Garla V, Gordon RA, Javaheri A, Jaeger CP, Leaes PE, Nassif M, Pursley M, Silveira FS, Barroso WKS, Lazcano Soto JR, Nigro Maia L, Berwanger O. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586–94.

    Article  CAS  Google Scholar 

  66. Sainsbury C, Wang J, Gokhale K, Acosta-Mena D, Dhalla S, Byne N, Chandan JS, Anand A, Cooper J, Okoth K, Subramanian A, Bangash MN, Taverner T, Hanif W, Ghosh S, Narendran P, Cheng KK, Marshall T, Gkoutos G, Toulis K, Thomas N, Tahrani A, Adderley NJ, Haroon S, Nirantharakumar K. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study. Diabetes Obes Metab. 2021;23(1):263–9.

    Article  CAS  Google Scholar 

  67. Das L, Dutta P. SGLT2 inhibition and COVID-19: the road not taken. Eur J Clin Investig. 2020;50(12):e13339.

    Article  CAS  Google Scholar 

  68. Sardu C, Marfella R, Prattichizzo F, La Grotta R, Paolisso G, Ceriello A. Effect of hyperglycemia on COVID-19 outcomes: vaccination efficacy, disease severity, and molecular mechanisms. J Clin Med. 2022;11(6):1564.

    Article  CAS  Google Scholar 

  69. Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes. 2021;11(1):21.

    Article  CAS  Google Scholar 

  70. Smati S, Tramunt B, Wargny M, Gourdy P, Hadjadj S, Cariou B. COVID-19 and diabetes outcomes: rationale for and updates from the CORONADO study. Curr Diab Rep. 2022;22(2):53–63.

    Article  CAS  Google Scholar 

  71. Yang Y, Cai Z, Zhang J. Insulin treatment may increase adverse outcomes in patients with COVID-19 and diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:696087.

    Article  Google Scholar 

  72. Yu B, Li C, Sun Y, Wang DW. Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes. Cell Metab. 2021;33(1):65–77.

    Article  CAS  Google Scholar 

  73. Katsiki N, Kotsa K, Stoian AP, Mikhailidis DP. Hypoglycaemia and cardiovascular disease risk in patients with diabetes. Curr Pharm Des. 2020;26(43):5637–49.

    Article  CAS  Google Scholar 

  74. Wang W, Sun Y, Wang S, Sun Y. The relationship between insulin use and increased mortality in patients with COVID-19 and diabetes: a meta-analysis. Endocr Res. 2022;47(1):32–8.

    Article  CAS  Google Scholar 

  75. Hariyanto TI, Lugito NPH, Yanto TA, Siregar JI, Kurniawan A. Insulin therapy and outcome from coronavirus disease 2019 (COVID-19): a systematic review, meta-analysis, and meta-regression. Endocr Metab Immune Disord Drug Targets. 2022;22(5):481–9. https://doi.org/10.2174/1871530321666210709164925.

    Article  Google Scholar 

  76. Hadjadj S, Wargny M. Glucose-lowering treatments and COVID-19 mortality in T2DM. Nat Rev Endocrinol. 2021;17(7):387–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece

    Niki Katsiki

  2. School of Medicine, European University Cyprus, Nicosia, Cyprus

    Niki Katsiki

  3. Department of Preventive Cardiology and Lipidology, Medical University of Łódź, Łódź, Poland

    Maciej Banach

  4. Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland

    Maciej Banach

Authors
  1. Niki Katsiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maciej Banach
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Łódź, Poland

    Maciej Banach

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Katsiki, N., Banach, M. (2022). Antidiabetic Drugs in COVID-19. In: Banach, M. (eds) Cardiovascular Complications of COVID-19. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-031-15478-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-15478-2_21

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-15477-5

  • Online ISBN: 978-3-031-15478-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation